{"task_id": "ac1c0efc6a3d0ea0", "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf (Part 423/905)", "text": "xazole. In severe disease: ceftazidime, meropenem.\n\n--- Page 429 ---\n415\nInfectious diseases\nExamination\nRash:\n  \n\u2022 Maculopapular: dengue, chikungunya, EBV, HIV seroconversion, VHF.\n  \n\u2022 Purpuric: dengue, meningococcal infection, plague, DIC, VHF.\n  \n\u2022 Ulcer: trypanosomiasis, Yesinia pestis, tick typhus, anthrax, tropical ulcer.\nJaundice: Viral hepatitis, severe falciparum malaria, enteric fever, leptospirosis, re-\nlapsing fever, typhus, VHF, bartonellosis\nHepatosplenomegaly: Viral hepatitis, HIV, enteric fever, brucellosis, leptospirosis, \nrickettsial infection, relapsing fever, schistosomiasis, amoebic liver abscess, trypa-\nnosomiasis, visceral leishmaniasis.\nInvestigation\nDirected by travel history and examination. In undiff erentiated fever:\n  \n\u2022 Malaria \ufb01 lm/rapid diagnostic testing (p417).\n  \n\u2022 HIV test (p399).\n  \n\u2022 FBC: lymphopenia in viral infection including HIV; eosinophilia in parasitic/fungal eg \nsoil-transmitted helminths, \ufb01 liariasis, schistosomiasis, hydatid disease; \ue001platelets \nin malaria, dengue, HIV, typhoid, severe sepsis.\n  \n\u2022 Blood culture \u22482: prior to antibiotics.\n  \n\u2022 LFT.\n  \n\u2022 Consider: save serum, speci\ufb01 c serology, or EDTA sample for PCR.\nSupport\n  \n\u2022 Local infectious diseases team (including on-call).\n  \n\u2022 Disease noti\ufb01 cation: www.gov.uk/health-protection-team.\n  \n\u2022 Public Health England imported fever service 0844 778 8990.\n  \n\u2022 National Travel Health Network and Centre (NaTHNaC)/TravelHealthPro\nwww.travelhealthpro.org.uk (0845 602 6712).\n  \n\u2022 Hospital for Tropical Diseases 0203 456 7890.\n  \n\u2022 Travel fever diagnostic website: www.fevertravel.ch\n~20 million cases and 200 000 deaths per year worldwide, ~500/yr in UK mostly im-\nported from India, Pakistan, and Bangladesh. Caused by related, Gram-negative \nstrains of \u2018typhoidal\u2019 Salmonella spp:\n  \n\u2022 Typhoid (~75\u201390%): Salmonella typhi.\n  \n\u2022 Paratyphoid (~10\u201325%, less severe): Salmonella paratyphi serotype A>B>C.\nThe bacteria invade the intestinal mucosa. Dissemination occurs without a pri-\nmary diarrhoeal response. This distinguishes \u2018typhoidal\u2019 from \u2018non-typhoidal\u2019 se-\nrovars of Salmonella which cause D&V (p428). Transmission is faecal\u2013oral from \ncontaminated water/food. Incubation 6\u201330d (most 10\u201320d). ~10 000 organisms are \nrequired to cause illness. Can be asymptomatic (but shed organism).\nSymptoms: Fatigue, headache, anorexia. Marked fever, \u2018stepwise\u2019 (rising through \neach day with progressive peaks) in <20%. Abdominal pain, relative bradycardia \n(Faget\u2019s sign), cough, constipation. Rose spots in ~25% (salmon-coloured, 1\u20134cm, \nblanching, due to bacterial emboli to dermis). Diarrhoea (\u2018pea-soup\u2019) and hepato-\nsplenomegaly in 2nd week. Progressive toxicity and complicated disease in up to \n10%: intestinal haemorrhage/perforation, myocarditis, hepatitis, pneumonia, DIC, \nCNS involvement (delirium, meningism, encephalitis, cerebellar signs, \ufb01 ts, coma), \neye complications (corneal ulcer, uveitis, neuritis, thrombosis).\nDiagnosis: Isolation of S. typhi from: blood (take multiple cultures of 10\u201315mL in \n\ufb01 rst 10d to \ue000 sensitivity), bone marrow, intestinal secretions, or stool (\ue000sensitivity \nafter 1st week). Serology has \ue001 sensitivity and speci\ufb01 city, not suffi  cient as sole \ndiagnostic tool (Widal test is \u03a9ve in ~30% of culture-proven cases). \ue000LFT. PCR (not \nroutine).\nTreatment: Azithromycin \u00b1 IV ceftriaxone. >70% imported from Asia are resistant \nto \ufb02 uoroquinolones. Fever takes median 5\u20137d to respond due to intracellular niche \nof organism. Antipyretics, \ufb02 uid management, nutrition. CNS disease: dexametha-\nsone 3mg/kg IV then 1mg/kg/6h for 8 doses (limited data).\nVaccine: Ty21a (oral, live, CI: immunosuppression, pregnancy) or Vi (IM, capsular \nvaccine). ~50\u201380% eff ective for ~3yr. Limited/no protection against paratyphoid.\nEnteric fever: typhoid and paratyphoid", "text_length": 3807, "metadata": {"source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf (Part 423/905)", "type": "chunk", "chunk_index": 422, "total_chunks": 905, "uploaded_by": "admin@admin.com", "upload_date": "2025-12-11T17:59:52.901125", "document_uuid": "1c4b3c41-9a74-4d3d-ab11-d2a041c9641f", "filename": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf", "category": "medical_pdf", "section": "body", "year": 2017, "outdated": false, "document_id": "1c4b3c41-9a74-4d3d-ab11-d2a041c9641f"}, "created_at": "2025-12-11T17:59:52.903068", "status": "complete", "chunks_added": 2}